Patient portal

Molenaar group

Precision medicine in pediatric cancer

The Molenaar group aims to develop new treatment options for pediatric cancer. We do this by connecting basic biological research to targeted therapies. New therapeutic options are eventually applied in clincal trials through our precision medicine program. Our translational work has a strong focus on neuroblastoma tumors.

Contact

Profile picture researcher

Jan Molenaar

Targeted drug development

Lead: Marlinde van den Boogaard

A highly efficient pipeline covering the full spectrum of targeted drug development is currently functional. The process starts with the validation of targets using high throughput analysis as Affymetrix mRNA profiling, RNAseq, Whole Genome Sequencing and single cell analysis. We are now building a dataset of over 500 neuroblastoma tumors for which WGS and RNA profiling data is available. We are performing integrative analysis on these samples that will allow identification of new driving events and relate genomic events to clinical subgroups within neuroblastoma. Potential new target genes are subsequently validated in cell line systems using a variety of molecular genetic manipulation techniques. The most promising target genes are then further validated using small molecule inhibitors in vitro and in vivo. Several new models are developed to consolidate this process. Tumor organoids are used and new in vivo xenograft and transgenic models are implemented. The current studies are in various stages of development and targets are MDM2, CDK4/6, CDKN2A, the MEK pathway, BCL2/MCL1, CHK1, ATRX and MTH1 in neuroblastoma with the CtoA mutator phenotype.

“The best treatment for every child”

Prof. dr. Jan Molenaar

Research group leader

Precision Medicine and Translational Pharmacology

Lead: Karin Langenberg

The aim of this subgroup is to develop more effective and less toxic treatments for children with cancer by translating preclinical discoveries into clinical practice. We combine molecular profiling with functional drug testing, primarily using patient-derived short-term cultures, complemented by organoids, cell lines, co-culture systems, and in vivo models.

In close collaboration with the High-Throughput Screening Facility and research groups within and beyond the Princess Máxima Center, candidate drugs and combinations are evaluated using clinically relevant concentrations and exposure schedules. Automated drug screening and high-content microscopy enable the characterization of tumour-specific and phenotypic responses in complex model systems. By integrating functional drug responses with tumour biology and PK/PD modelling, we investigate efficacy, target engagement, tissue exposure, tolerability, and biomarkers of response and resistance. This approach is being further expanded through single-cell analyses and AI-supported data integration to address tumour heterogeneity and improve treatment-response predictions. 

International collaboration is central to our work. Together with leading paediatric oncology and drug-screening centres, we harmonize methodologies, share data and expertise, and validate treatment strategies across institutions. Ultimately, our ambition is to prioritize effective therapeutic interventions for clinical implementation and evaluation, accelerating access to more precise, effective, and less toxic treatments for children with cancer.

 

Compound screening and chemistry

Lead: Selma Eising

The aim of this project is to identify and validate new treatment options in pediatric cancer using the high throughput screening facility. The two major objectives are: 1) The coordination of compound screening facility which has become available in 2019. It contains a state of the art BeckmanCoulter robotics set-up including an Echo550 compound dispenser system. The facility runs many screens for different research groups in the Máxima center. 2) The incorporation of in vitro model systems to validate potential interventions, identify new interventions and identify potential combination treatment options for patients without curative options, as a part of the iTHER precision medicine program.

Furthermore, a new line of research is set up that aims to use a novel class of drugs called PROteolysis Targeting Chimerase (PROTACs) for the treatment of neuroblastoma. In the Molenaar group, we have identified frequent chromosomal rearrangement and genomic aberrations that are driving neuroblastoma. Two of these specific oncogenic drivers are defined as ‘un-targetable’, because they cannot be targeted using existing drugs. In collaboration with the Utrecht Institute of Pharmaceutical Sciences, we aim to selectively degrade the tumor-target proteins using PROTACs.

Grants and awards

Key publications

Join us

To cure every child with cancer, we are looking for the best scientists! Working in a top organization demands highly qualified employees who perform to their utmost in a work environment with continuous motivation for improvement. Do you recognize yourself in our core values as groundbreaking and passionate? Explore the job opportunities in our research department.

Explore job opportunities